Search

Introducción: La estratificación del riesgo de complicaciones mayores (incluyendo mortalidad) es, en la actualidad, la estrategia clínica fundamental para la toma de decisiones terapéuticas en pacientes con hipertensión arterial pulmonar. Sin embargo, es llamativo que la mayoría de pacientes se agrupan en la categoría intermedia, tanto en el momento del diagnóstico como en el seguimiento, con lo cual se hace relevante y necesario mejorar la discriminación y las opciones terapéuticas de los pacientes en riesgo intermedio. Objetivo: Definir una serie de recomendaciones sobre la propia subclasificación, el seguimiento y el tratamiento de pacientes adultos con hipertensión arterial pulmonar en riesgo intermedio adaptadas al contexto colombiano. Método: Se invitaron 15 expertos en hipertensión pulmonar quienes votaron de acuerdo con la metodología Delphi modificada en torno a catorce preguntas, sobre las cuales se realizó una revisión sistemática de la literatura en varias bases bibliográficas: BVS, Cochrane Library, PubMed, Medline y Web of Science. Se utilizaron los criterios MeSh y DeCs para cada pregunta, sin límite de idioma o tiempo. Resultados y discusión: El principal elemento de valor de la investigación está representado por dieciocho recomendaciones consensuadas sobre estratificación, tratamiento y otros apartados. Adicionalmente, la iniciativa permite identificar la escasez de estudios científicos que determinen el comportamiento de la enfermedad, las barreras de acceso y la disponibilidad de medicamentos en Colombia.

AIMED, Chía, Colombia; 7Andean Cluster - Respiratory & Immunology, AstraZeneca, Bogotá, Colombia; 8Respiratory & Immunology AstraZeneca, The Hague, the NetherlandsCorrespondence: John Carlos Pedrozo-Pupo, PREVICARE LTDA. Programa de Medicina, Facultad de Ciencias de la Salud, Universidad del Magdalena, Santa Marta, Colombia, Tel +57 603017384712, Email [email protected] Purpose: Overuse of short-acting β2-agonists (SABAs) for asthma is associated with a significant increase in exacerbations and healthcare resource use. However, limited data exist on the extent of SABA overuse outside of Europe and North America. As part of the multi-country SABA use IN Asthma (SABINA) III study, we characterized SABA prescription patterns in Colombia. Patients and Methods: This observational, cross-sectional cohort study of SABINA III included patients (aged ≥ 12 years) with asthma recruited from seven sites in Colombia. Demographics, disease characteristics (including investigator-defined asthma severity guided by the 2017 Global Initiative for Asthma report), and asthma treatments prescribed (including SABAs and inhaled corticosteroids [ICS]) in the 12 months preceding the study were recorded using electronic case report forms during a single study visit. Results: Of 250 patients analyzed, 50.4%, 33.2%, and 16.4% were enrolled by pulmonologists, general medicine practitioners, and allergists, respectively. Most patients were female (74.0%) and had moderate-to-severe asthma (67.6%). Asthma was partly controlled or uncontrolled in 57.6% of patients, with 15.6% experiencing ≥ 1 severe exacerbation 12 months before the study visit. In total, 4.0% of patients were prescribed SABA monotherapy and 55.6%, SABA in addition to maintenance therapy. Overall, 39.2% of patients were prescribed ≥ 3 SABA canisters in the 12 months before the study visit; 25.2% were prescribed ≥ 10 canisters. Additionally, 17.6% of patients purchased SABAs over the counter, of whom 43.2% purchased ≥ 3 canisters. Maintenance medication in the form of ICS or ICS/long-acting β2-agonist fixed-dose combination was prescribed to 36.0% and 66.8% of patients, respectively. Conclusion: Our findings suggest that prescription/purchase of ≥ 3 SABA canisters were common in Colombia, highlighting a public health concern. There is a need to improve asthma care by aligning clinical practices with the latest evidence-based treatment recommendations to improve asthma management across Colombia. [ABSTRACT FROM AUTHOR]